Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies-Reference-Cited by-同舟云学术

Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies

Published:2017-03-22 Issue:5 Volume:24 Page:726-733
ISSN:1351-5101
Container-title:European Journal of Neurology
language:en
Short-container-title:Eur J Neurol

Author:

Havrdova E.¹,Giovannoni G.²,Gold R.³,Fox R. J.⁴,Kappos L.⁵,Phillips J. Theodore⁶,Okwuokenye M.⁷,Marantz J. L.⁷

Affiliation:

1. Department of Neurology; First Faculty of Medicine; Charles University; Prague Czech Republic

2. Queen Mary University of London; Blizard Institute; London UK

3. St Josef Hospital; Ruhr University; Bochum Germany

4. Mellen Center for Multiple Sclerosis Treatment and Research; Cleveland Clinic; Cleveland OH USA

5. Neurologic Clinic and Policlinic; University Hospital; Basel Switzerland

6. Multiple Sclerosis Program; Baylor Institute for Immunology Research; Dallas TX USA

7. Biogen; Cambridge MA USA

Publisher

Wiley

Subject

Neurology (clinical),Neurology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/ene.13272/fullpdf

Reference19 articles.

1. Effect of Natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study;Havrdova;Lancet Neurol,2009

2. Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis;Arnold;BMC Neurol,2014

3. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis;Nixon;Adv Ther,2014

4. Is it time to target no evident disease activity (NEDA) in multiple sclerosis?;Giovannoni;Mult Scler Relat Disord,2015

5. Rudick R Fisher E Goodman A et al No evident disease activity (NEDA): associations with brain atrophy and functional outcomes in patients from the AFFIRM study 2014

Cited by 51 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis;Cochrane Database of Systematic Reviews;2024-01-04

2. Treatment algorithms of relapsing multiple sclerosis: an exploration based on the available disease-modifying therapies in China;Therapeutic Advances in Neurological Disorders;2024-01

3. No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review];Neurology and Therapy;2023-10-11

4. The evolution of multiple sclerosis disease-modifying therapies: An update for pharmacists;American Journal of Health-System Pharmacy;2023-10-01

5. NRF2, a Superstar of Ferroptosis;Antioxidants;2023-09-08